COVID-19: EPIDEMIOLOGY, PATHOGENICITY AND GLOBAL UPDATES

  • MANJINDER SINGH Chitkara College of Pharmacy, Chitkara University, Punjab, India
  • MANJU NAGPAL Chitkara College of Pharmacy, Chitkara University, Punjab, India
  • VARINDER SINGH Chitkara College of Pharmacy, Chitkara University, Punjab, India
  • AMEYA SHARMA Chitkara College of Pharmacy, Chitkara University, Punjab, India, Chitkara University School of Pharmacy, Chitkara University, Himachal Pradesh, India
  • GITIKA ARORA DHINGRA NCRD’s Sterling Institute of Pharmacy, Nerul, Navi Mumbai, India
  • PARAMJOT MAMAN Paraxel International Ltd, Mohali, Punjab, India
  • VIVEK PURI Chitkara College of Pharmacy, Chitkara University, Punjab, India, Chitkara University School of Pharmacy, Chitkara University, Himachal Pradesh, India

Abstract

Novel coronavirus (COVID-19) is a highly contagious virus that originated from China and has become a major threat in the current time. Presently, finding an effective treatment strategy for COVID-19 is in infancy. Worldwide, numerous clinical trials employing different treatment strategies (antiviral drugs and vaccines) are in progress to develop an effective therapeutic regimen against COVID-19. Literature related to the epidemiology, mortality, pathogenicity, treatment strategies and clinical data was studied and database was collected using various search engines such as j-gate, google scholar, scihub, pubmed, sciencedirect etc. The present review systematically summarises the published information about epidemiology, various stages of pandemic, mortality, pathogenicity, modes of transmission, clinical characteristics, methods of prevention, ongoing treatment strategies and drugs under clinical trials associated with COVID-19 with a hope to avoid possible threatening of the lives of millions of human beings and provide directions for future studies.

Keywords: COVID-19, Coronavirus, Epidemiology, Pathology, Zoonotic, Prevention and Treatment

References

1. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents 2020;55:105924.
2. Gralinski LE, Menachery VD. Return of the coronavirus: 2019-nCoV. Viruses 2020;12:135.
3. Liu C, Zhou Q, Li Y, Garner LV, Watkins SP, Carter LJ, et al. Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. ACS Cent Sci 2020;6:315?31.
4. Carlos WG, Dela Cruz CS, Cao B, Pasnick S, Jamil S. Novel wuhan (2019-nCoV) coronavirus. Am J Respir Crit Care Med Vol 2020;201:P7-8.
5. Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in wuhan china: the mystery and the miracle. J Med Virol 2020;92:401–2.
6. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet 2020;395:470-3.
7. Lee A. Wuhan novel coronavirus (Covid-19): why global control is challenging?. Public Health 2020;179:A1-2.
8. Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol 2020;92:418-23.
9. Seah I, Su X, Lingam G. Revisiting the dangers of the coronavirus in the ophthalmology practice. Eye 2020;34:1155-7.
10. Hassan S, Sheikh FN, Jamal S, Ezeh JK, Akhtar A. Coronavirus (COVID-19): a review of clinical features, diagnosis, and treatment. Cureus 2020;12:e7355.
11. Statista. Covid-19/Coronavirus; 2020. Available from: https://www.statista.com/page/covid-19-coronavirus. [Last accessed on 24 May 2020]
12. World Health Organization (WHO). Coronavirus disease (COVID-19) pandemic. Coronavirus disease (COVID-19) outbreak situation; 2020. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019. [Last accessed on 24 May 2020]
13. Dhama K, Sharun K, Tiwari R, Sircar S, Bhat S, Malik YS, et al. Coronavirus disease 2019–COVID-19. Preprints 2020:2020030001.
14. Sun J, He WT, Wang L, Lai A, Ji X, Zhai X, et al. COVID-19: epidemiology, evolution, and cross-disciplinary perspectives. Trends Mol Med 2020;26:483-95.
15. Munster VJ, Koopmans M, van Doremalen N, van Riel D, de Wit E. A novel coronavirus emerging in China—key questions for impact assessment. N Engl J Med 2020;382:692-4.
16. El Zowalaty ME, Jarhult JD. From SARS to COVID-19: A previously unknown SARS-CoV-2 virus of pandemic potential infecting humans–call for a one health approach. One Health 2020;9:100124.
17. Ren SY, Gao RD, Chen YL. Fear can be more harmful than the severe acute respiratory syndrome coronavirus 2 in controlling the corona virus disease 2019 epidemic. World J Clin Cases 2020;8:652.
18. Chang D, Lin M, Wei L, Xie L, Zhu G, Cruz CS, et al. Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside Wuhan, China. JAMA 2020;323:1092-3.
19. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun 2020;109:102433.
20. Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet 2020;395:689-97.
21. Wang J, Wang Z. Strengths, weaknesses, opportunities and threats (swot) analysis of china’s prevention and control strategy for the covid-19 epidemic. Int J Environ Res Public Health 2020;17:2235.
22. Li H, Liu SM, Yu XH, Tang SL, Tang CK. Coronavirus disease 2019 (Covid-19): Current status and future perspective. Int J Antimicrob Agents 2020;55:105951.
23. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020;395:514-23.
24. Cheng ZJ, Shan J. 2019 Novel coronavirus: where we are and what we know. Infection 2020;48:155-63.
25. Xinhua; 2020. Available form: http://www.xinhu anet.com/politics/2020-01/28/c_1125506707.htm. [Last accessed on 24 May 2020]
26. Pan F, Ye T, Sun P, Gui S, Liang B, Li L, et al. Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia. Radiology 2020;295:200370.
27. Callanan J, Stockdale SR, Shkoporov A, Draper LA, Ross RP, Hill C. RNA phage biology in a metagenomic era. Viruses 2018;10:386.
28. Guo R, Shang P, Carrillo CA, Sun Z, Lakshmanappa YS, Yan X, et al. Double-stranded viral RNA persists in vitro and in vivo during prolonged infection of porcine reproductive and respiratory syndrome virus. Virology 2018;524:78-89.
29. Chan JF, Kok KH, Zhu Z, Chu H, To KK, Yuan S, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect 2020;9:221-36.
30. Fuenmayor J, Godia F, Cervera L. Production of virus-like particles for vaccines. New biotechnol 2017;39:174-80.
31. Dong N, Yang X, Ye L, Chen K, Chan EW, Yang M, et al. Genomic and protein structure modelling analysis depicts the origin and infectivity of 2019-nCoV, a new coronavirus which caused a pneumonia outbreak in Wuhan, China. bioRxiv 2020. https://doi.org/10.1101/2020.01.20.913368
32. Wang LS, Wang YR, Ye DW, Liu QQ. A review of the 2019 novel coronavirus (COVID-19) based on current evidence. Int J Antimicrob Agents 2020;55:105948.
33. Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. J Adv Res 2020;24:91-8.
34. Wang Y, Li X, Liu W, Gan M, Zhang L, Wang J, et al. Discovery of a subgenotype of human coronavirus NL63 associated with severe lower respiratory tract infection in China, 2018. Emerg Microbes Infect 2020;9:246-55.
35. Ladimo MP, Irwan I. MERS-CoV (Middle East Respiratory Syndrome-Corona Virus) menggegerkan dunia timur. J Health Sci: Gorontalo J Health Sci Community 2020;4:18-28.
36. Chaudhary NK. Outbreak of coronavirus disease (COVID-19). J Chitwan Med Coll 2020;10:1-2.
37. Malik YS, Sircar S, Bhat S, Vinodhkumar OR, Tiwari R, Sah R, et al. Emerging coronavirus disease (covid-19), a pandemic public health emergency with animal linkages: current status update. Preprints 2020;90:2020030343.
38. Zhang L, Liu Y. Potential interventions for novel coronavirus in China: a systematic review. J Med Virol 2020;92:479-90.
39. Rasool A, Ishfaq S, Uqab B. Novel coronavirus (2019-nCoV) Outbreak in China: From Local Epidemics to Global Pandemics; 2020.
40. Schoeman D, Fielding BC. Coronavirus envelope protein: current knowledge. Virol J 2019;16:69.
41. Deng X, Volk A, Chen Y, Kesely KR, Hackbart M, Mettelman RC, et al. Coronavirus interferon antagonists differentially modulate the host response during replication in macrophages. bioRxiv 2019. https://doi.org/10.1101/782409
42. Abassi ZA, Skorecki K, Heyman SN, Kinaneh S, Armaly Z. Covid-19 infection and mortality-A physiologist's perspective enlightening clinical features and plausible interventional strategies. Am J Physiol Lung Cell Mol Physiol 2020. https://doi.org/10.1152/ajplung.00097.2020
43. Kang S, Peng W, Zhu Y, Lu S, Zhou M, Lin W, et al. Recent progress in understanding 2019 novel coronavirus associated with human respiratory disease: detection, mechanism and treatment. Int J Antimicrob Agents 2020;55:105950.
44. Dou D, Revol R, Ostbye H, Wang H, Daniels R. Influenza a virus cell entry, replication, virion assembly and movement. Front Immunol 2018;9:1581.
45. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with covid-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054-62.
46. Poon LL, Peiris M. Emergence of a novel human coronavirus threatening human health. Nat Med 2020;26:317-9.
47. Peeri NC, Shrestha N, Rahman MS, Zaki R, Tan Z, Bibi S, et al. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned?. Int J Epidemiol 2020;49:717-26.
48. Zhang YZ, Holmes EC. A genomic perspective on the origin and emergence of SARS-CoV-2. Cell 2020;181:223-7.
49. Ralph R, Lew J, Zeng T, Francis M, Xue B, Roux M, et al. 2019-nCoV (Wuhan virus), a novel Coronavirus: human-to-human transmission, travel-related cases, and vaccine readiness. J Infect Dev Countrol 2020;14:3-17.
50. Yang Y, Peng F, Wang R, Guan K, Jiang T, Xu G, et al. The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. J Autoimmun 2020;109:102434.
51. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature 2020;579:265-9.
52. Ye ZW, Yuan S, Yuen KS, Fung SY, Chan CP, Jin DY. Zoonotic origins of human coronaviruses. Int J Biol Sci 2020;16:1686.
53. Dilcher M, Werno A, Jennings LC. SARS-CoV-2: a novel deadly virus in a globalised world. N Z Med J 2020;133:6-11.
54. Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet 2020;395:809-15.
55. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.
56. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;79:270-3.
57. Gormley M, Aspray TJ, Kelly DA. COVID-19: mitigating transmission via wastewater plumbing systems. Lancet Glob Health 2020;8:e643.
58. Wu JT, Leung K, Bushman M, Kishore N, Niehus R, de Salazar PM, et al. Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China. Nat Med 2020;26:506-10.
59. Hellewell J, Abbott S, Gimma A, Bosse NI, Jarvis CI, Russell TW, et al. Feasibility of controlling covid-19 outbreaks by isolation of cases and contacts. Lancet Glob Health 2020;8:e488-e496.
60. Prem K, Liu Y, Russell TW, Kucharski AJ, Eggo RM, Davies N, et al. The effect of control strategies to reduce social mixing on outcomes of the covid-19 epidemic in Wuhan, China: a modelling study. Lancet Public Health 2020;5:e261-e270.
61. World Health Organization. Severe acute respiratory infections treatment centre: practical manual to set up and manage a SARI treatment centre and a SARI screening facility in health care facilities. World Health Organization 2020. Available from: https://apps.who.int/iris/bitstream/handle/10665/331603/WHO-2019-nCoV-SARI_treatment_center-2020.1-eng.pdf. [Last accessed on 24 May 2020]
62. Wickramasinghe NC, Steele EJ, Gorczynski RM, Temple R, Tokoro G, Wallis DH, et al. Growing evidence against global infection-driven by person-to-person transfer of covid-19. Virol Curr Res 2020;4:110.
63. World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance, 13 March 2020. World Health Organization; 2020. Available from: https://apps.who.int/iris/bitstream/handle/10665/331446/WHO-2019-nCoV-clinical-2020.4-eng.pdf. [Last accessed on 20 May 2020]
64. Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA 2020;323:1406-7.
65. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, evaluation and treatment coronavirus (COVID-19). In: StatPearls. StatPearls Publishing; 2020.
66. Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. Br Med J 2020;368:m606.
67. Centers for disease control and prevention. How COVID-19 spreads; 2020. Available from: https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/how-covid-spreads.html [Last accessed on 23 May 2020]
68. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak–an update on the status. Mil Med Res 2020;7:1-10.
69. Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Bondi Zoccai G, et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (Covid-19) pandemic. J Am Coll Cardiol 2020;S0735-1097:34637-44.
70. Centers for disease control and prevention. Symptoms of coronavirus; 2020. Availabe from: https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html [Last accessed on 24 May 2020]
71. World Health organization (WHO). Coronavirus; 2020. Available from: https://www.who.int/health-topics/coronavirus#tab=tab_3 [Last accessed on 23 May 2020]
72. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA 2020;323:1061-9.
73. Wang Y, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID?19) implicate special control measures. J Med Virol 2020;92:568-76.
74. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507-13.
75. Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, Xia Z. Review of the clinical characteristics of coronavirus disease 2019 (COVID-19). J Gen Intern Med 2020;35:1545-9.
76. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020;323:1239-42.
77. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther 2020;14:58-60.
78. National Health Commission. Notice regarding the issuance of a new coronavirus pneumonia diagnosis and treatment plan; 2020. Available from: http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2/files/b218cfeb1bc54639af227f9 22bf6b817.pdf [Last accessed on 24 May 2020]
79. Wang Y, Zhu LQ. Pharmaceutical care recommendations for antiviral treatments in children with coronavirus disease 2019. World J Pediatr 2020;16:1-4.
80. Ministry of Health and Family Welfare Directorate General of Health Services. Advisory for Human Resource Management of COVID-19; 2020. Available from: https://www.mohfw.gov.in/pdf/AdvisoryforHRmanagement.pdf. [Last accessed on 23 May 2020]
81. Savarino A, Di Trani L, Donatelli I, Cauda R, Cassone A. New insights into the antiviral effects of chloroquine. Lancet Infect Dis 2006;6:67-9.
82. Yan Y, Zou Z, Sun Y, Li X, Xu KF, Wei Y, et al. Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell Res 2013;23:300-2.
83. Colson P, Rolain J, Raoult D. Chloroquine for the 2019 novel coronavirus SARS-CoV-2. Int J Antimicrob Agents 2020;55:105923.
84. Hafid AF. The combination therapy model of andrographis paniculata extract and chloroquine on plasmodium berghei infected mice. Asian J Pharm Clin Res 2015;8:205-8.
85. Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, et al. Lopinavir–ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002;346: 2039-46.
86. Pulido F, Arribas JR, Delgado R, Cabrero E, Gonzalez Garcia J, Perez Elias MJ, et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. AIDS 2008;22:F1-9.
87. Lin S, Shen R, Guo X. Molecular modeling evaluation of the binding abilities of ritonavir and lopinavir to wuhan pneumonia coronavirus proteases. bioRxiv 2020. https://doi.org/10.1101/2020.01.31.929695
88. Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004;59:252-6.
89. Sheahan TP, Sims AC, Leist SR, Schafer A, Won J, Brown AJ, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 2020;11:222.
90. Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses-drug discovery and therapeutic options. Nat Rev Drug Discovery 2016;15:327.
91. de Wit E, Feldmann F, Cronin J, Jordan R, Okumura A, Thomas T, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. P Natl Acad Sci 2020;117:6771-6.
92. Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio 2018;9:e00221-18.
93. Kapoor KM, Kapoor A. Role of chloroquine and hydroxychloroquine in the treatment of COVID-19 infection-A systematic literature review. medRxiv 2020. DOI:10.1101/2020.03.24.20042366
94. A PK, G P, Sn M, Ap S, Swamy V, Rama S. Clinical outcomes of use of hydroxychloroquine in paradoxical tuberculosis-immune reconstitution inflammatory syndrome in hiv-infected patients. Asian J Pharm Clin Res 2018;11:439-41.
95. Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discovery 2020;6:16.
96. Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe Covid-19 patients with Tocilizumab. ChinaXiv preprint; 2020. Available from: https://www.ser.es/wp-content/uploads/2020/03/TCZ-and-COVID-19.pdf [Last accessed on 24 May 2020]
97. UPHARMA Consulting healthcare. Available from: https://www.upharma-c.com/en/ [Last accessed on 24 May 2020]
98. Zhang S, Diao MY, Duan L, Lin Z, Chen D. The novel coronavirus (SARS-CoV-2) infections in China: prevention, control and challenges. Intensive Care Med 2020;46:591-3.
99. Jordan V. Coronavirus (Covid-19): infection control and prevention measures. J Prim Health Care 2020;12:96-7.
Statistics
93 Views | 42 Downloads
Citatons
How to Cite
SINGH, M., NAGPAL, M., SINGH, V., SHARMA, A., DHINGRA, G. A., MAMAN, P., & PURI, V. (2020). COVID-19: EPIDEMIOLOGY, PATHOGENICITY AND GLOBAL UPDATES. International Journal of Applied Pharmaceutics, 12(5), 16-28. https://doi.org/10.22159/ijap.2020v12i5.38439
Section
Review Article(s)